PANAXEA BV

Their core work

PANAXEA is a Dutch SME specializing in the intersection of automation, data science, and biomedical manufacturing. They provide expertise in automated production systems for advanced therapies (such as CAR-T cells and stem cell products), including bioreactor process monitoring, GMP/GAMP compliance, and economic analysis. More recently, they work on digital twins, smart bioprocessing, and cyber-physical systems applied to hospital-based decentralized manufacturing of personalized medicines.

What they specialise in

How they've shifted over time

PANAXEA's early H2020 work (2016–2019) centered on health data and clinical research — neonatal lung device monitoring (CRADL) and cardiac arrest epidemiology (ESCAPE-NET). From 2020 onward, they shifted decisively toward automated biomanufacturing and digital production systems, with keywords like bioreactors, digital twins, IoT, and smart hospitals replacing epidemiology and cohort studies. This evolution suggests a company that moved from supporting clinical research to becoming a specialist in the digitalization and automation of advanced therapy manufacturing.

PANAXEA is moving toward decentralized, hospital-based smart manufacturing of personalized medicines — a rapidly growing field where automation, regulatory compliance, and digital process control converge.

How they like to work

PANAXEA has exclusively participated as a partner, never as coordinator, across all four projects. They work in medium-to-large consortia (46 unique partners across 16 countries), suggesting they contribute specialized expertise to larger teams rather than leading them. Their broad partner base with no repeated patterns indicates they are sought out by diverse consortia for their niche capabilities rather than operating within a fixed network.

PANAXEA has collaborated with 46 unique partners across 16 countries, indicating a wide European network despite their small size. Their partnerships span clinical research institutions, universities, and technology developers across Western and Southern Europe.

What sets them apart

PANAXEA occupies a rare niche at the intersection of digital automation (IoT, digital twins, machine learning) and GMP-compliant advanced therapy manufacturing. While many SMEs focus on either the digital or the biomedical side, PANAXEA bridges both — making them valuable for projects that need to translate lab-scale cell therapy processes into automated, regulation-ready hospital production. Their combined expertise in economic analysis and regulatory compliance (GMP/GAMP) adds a practical commercialization dimension that purely technical partners often lack.

Highlights from their portfolio

• AIDPATH
  Their largest project (EUR 348K) and most representative of their current direction: AI-driven decentralized production of advanced therapies in hospitals, combining digital twins, IoT, and smart bioprocessing.
• AutoCRAT
  Demonstrates their biomanufacturing core — automated robot-assisted technologies for stem cell and extracellular vesicle production with full GMP/GAMP regulatory compliance focus.